CADL Candel Therapeutics, Inc.

Nasdaq candeltx.com


$ 5.43 $ -0.09 (-1.66 %)    

Friday, 17-Oct-2025 19:02:46 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 5.33
$ 5.35
$ 5.26 x 500
$ 6.00 x 1,987
$ 5.26 - $ 5.51
$ 3.79 - $ 14.60
726,408
na
292.59M
$ 0.92
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-29-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 09-08-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company's financial position; ...

 candel-therapeutics-reports-glioblastoma-trial-data-as-study-reveals-can-3110-triggers-immune-driven-tumor-remodeling-in-the-journal-science-translational-medicine

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developi...

 hc-wainwright--co-reiterates-buy-on-candel-therapeutics-maintains-23-price-target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ: CADL) with a Buy and maintains $...

 candel-therapeutics-announces-can-2409-significantly-improves-disease-free-survival-in-prostate-cancer-showing-benefit-across-radiation-modalities-in-phase-3-trial

CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to place...

 b-of-a-securities-downgrades-candel-therapeutics-to-neutral-lowers-price-target-to-7

B of A Securities analyst Alec Stranahan downgrades Candel Therapeutics (NASDAQ:CADL) from Buy to Neutral and lowers the pri...

 candel-therapeutics-files-for-mixed-shelf-of-upto-300m

- SEC Filing

 candel-therapeutics-q2-eps-009-beats-017-estimate

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $...

 candel-therapeutics-secures-ema-orphan-designation-for-can-2409-for-treatment-of-pancreatic-cancer

andel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developin...

 candel-therapeutics-added-to-multiple-russell-value-indexes-in-2025-reconstitution

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developi...

 hc-wainwright--co-assumes-candel-therapeutics-at-buy-announces-price-target-of-23

HC Wainwright & Co. analyst Andrew Fein assumes Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price ...

 candel-therapeutics-announces-15m-registered-direct-offering-of-32m-shares-at-467-per-share

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developi...

 candel-therapeutics-cadl-stock-is-surging-wednesday-whats-going-on

Candel Therapeutics stock rose after its prostate cancer therapy, CAN-2409, received FDA RMAT designation. This expedites devel...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION